- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
- Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
- Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
- Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Tuesday, Acumen Pharmaceuticals Inc (ABOS:NSQ) closed at 3.16, 74.58% above the 52 week low of 1.81 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.19 |
---|---|
High | 3.32 |
Low | 3.14 |
Bid | 3.11 |
Offer | 3.90 |
Previous close | 3.16 |
Average volume | 288.30k |
---|---|
Shares outstanding | 60.08m |
Free float | 54.60m |
P/E (TTM) | -- |
Market cap | 189.85m USD |
EPS (TTM) | -1.08 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼